Provided by Tiger Trade Technology Pte. Ltd.

TEMA ONCOLOGY ETF

44.84
-0.3909-0.86%
Volume:16.48K
Turnover:740.94K
Market Cap:217.05M
PE:- -
High:45.22
Open:45.22
Low:44.51
Close:45.24
52wk High:47.00
52wk Low:26.52
Shares:4.84M
Float Shares:4.84M
Volume Ratio:0.56
T/O Rate:0.34%
Dividend:0.02
Dividend Rate:0.04%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

China's Drug Regulator Accepts Novo Nordisk's Application for Oral Wegovy

Reuters
·
3 hours ago

Revolution Medicines, Inc. : Oppenheimer Raises Target Price to $260 from $230

THOMSON REUTERS
·
5 hours ago

Eli Lilly & Co. Stock Slips 3.6%, Underperforms Peers

Dow Jones
·
11 hours ago

Sector Update: Healthcare

MT Newswires Live
·
13 hours ago

Roche receives FDA approval for companion diagnostic tests for Ziihera

TIPRANKS
·
13 hours ago

Revolution Medicines Prices Metastatic Pancreatic Cancer Drug Rasonque at $39,800 a Month

MT Newswires Live
·
14 hours ago

Revolution Medicines to Charge $39,800 a Month for Pancreatic Cancer Drug, Bloomberg Reports

MT Newswires Live
·
14 hours ago

Revolution Medicines - Rasonque is NOW Commercially Available in the U.S. at a Wholesale Acquisition Cost of $39,800 for a 30-Day Supply - Conf Call

THOMSON REUTERS
·
14 hours ago

Revolution Medicines Posts Investor Presentation on Rasonque FDA Approval

Reuters
·
14 hours ago

Revolution Medicines prices Rasonque at $39,800 for 30-day supply

TIPRANKS
·
14 hours ago

Revolution Medicines announces FDA approval of Rasonque in adults

TIPRANKS
·
15 hours ago

Revolution Medicines, - Rasonque 300 Mg Once-Daily Oral Tablets NOW Available in the U.S.

THOMSON REUTERS
·
15 hours ago

U.S. FDA Approves Revolution Medicines’ Rasonque™ (Daraxonrasib), the First Broad Ras-Targeted Medicine in Metastatic Pancreatic Cancer

THOMSON REUTERS
·
15 hours ago

U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer

GlobeNewswire
·
15 hours ago

Eli Lilly Expands Alzheimer’s Pipeline With New Amyloid Phase 1 Trial

TIPRANKS
·
16 hours ago

Eli Lilly Stock (LLY) in Focus as Alzheimer’s Blood Test Gets FDA Approval

TIPRANKS
·
Yesterday

FDA Approves Drug for Pancreatic Cancer in Incredible Moment for Deadly Disease

Dow Jones
·
Yesterday

US FDA Approves Revolution Medicines' Pancreatic Cancer Drug

Reuters
·
Yesterday

FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer

THOMSON REUTERS
·
Yesterday

Eli Lilly and Co Stock (LLY) Opened Down by 3.57% on Aug 26: Facts Behind the Movement

TradingKey
·
Yesterday